M4 Positive Allosteric Modulators for Selective Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction, such as schizophrenia and Alzheimer's disease, face challenges due to the lack of highly selective activators for the M4 subtype of muscarinic acetylcholine receptors, leading to adverse effects from activation of peripheral receptors.
Innovation Solution
Development of compounds that act as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4), binding to an allosteric site distinct from the orthosteric site to augment receptor activity, potentially reducing adverse effects and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AChE inhibitors are used to increase acetylcholine levels, then therapeutic efficacy for cognitive deficits is improved, but cholinergic side effects and hepatotoxicity increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (aromatic ring systems with particular substituent patterns) that confer selectivity for M1 and M3 muscarinic acetylcholine receptors over other receptor subtypes. This selective receptor activation localizes the therapeutic effect to cognitive functions while minimizing peripheral cholinergic side effects
Solution Approach 2:
The invention segments the muscarinic acetylcholine receptor family into distinct therapeutic targets (M1 and M3 subtypes) and develops compounds that selectively activate these specific subtypes. This segmentation allows for targeted cognitive enhancement without activating receptors responsible for peripheral side effects
2Adaptability or versatility
If selective M4 agonists are developed to target cognitive function, then therapeutic specificity is improved, but compound selectivity remains insufficient leading to peripheral receptor activation
Solution Approach 1:
The patent employs local quality by incorporating specific structural motifs (such as particular aromatic ring configurations and substituent arrangements) that create high affinity and selectivity for M1 and M3 receptors. These localized structural features ensure selective binding to the desired receptor subtypes while excluding other muscarinic receptor subtypes
3Quantity of substance
If choline or phosphatidylcholine is administered to augment central cholinergic function, then acetylcholine precursor availability is improved, but therapeutic success is not achieved
Solution Approach 1:
The invention applies parameter changes by transitioning from increasing acetylcholine precursor availability (choline administration) to direct receptor activation with selective agonists. This fundamental parameter change in the mechanism of action bypasses the limitations of precursor supplementation and achieves reliable therapeutic effects through targeted receptor engagement
Data Source
AI summary
Deuterium-labeled 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidines substituted with pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.